Studies have approved PD-1 antibodies (pembrolizumab, cemiplimab, and nivolumab), as well as PD-L1 antibodies (durvalumab, avelumab, and atezolizumab) for several cancer types, including AML [195]. This evidence concerns the gene CD274 and acute myeloid leukemia.